Pankaj Khandelwal, MD
Medical Oncology · Odessa, TXNPI 1114964756
Payments from drug & device makers
What this record shows
3 manufacturers reported payments, led by Genentech USA, Inc. at 47.3% of the total. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 3 payments — averaging $42.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$60
- Intuitive Surgical$55
- Gilead$12
Across 71 payments — averaging $4142.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$129K
- Pfizer$66K
- E.r. Squibb & Sons, L.L.C.$63K
- Janssen Research & Development, LLC$21K
- Mirati Therapeutics, Inc.$14K
- Bristol Myers Squibb$952
What the payments were for
- Food & beverage$5543%
- Education$7257%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 1 | $60 |
| Intuitive Surgical | 1 | $55 |
| Gilead | 1 | $12 |
How this compares
$127 in reported general payments places this provider in the 10th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 42 | $648,715 |
| RevlimidLenalidomide | 25 | $435,099 |
| ImbruvicaIbrutinib | 17 | $251,016 |
| XtandiEnzalutamide | 18 | $226,478 |
| Lenalidomide | 19 | $215,903 |
| InlytaAxitinib | 18 | $185,302 |
| Imatinib Mesylate | 21 | $100,289 |
| Abiraterone Acetate | 35 | $96,213 |
| CalquenceAcalabrutinib Maleate | 12 | $93,966 |
| EliquisApixaban | 32 | $19,655 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 105 | $3,084 |
| Morphine Sulfate ErMorphine Sulfate | 34 | $1,734 |
| Tamoxifen Citrate | 78 | $1,455 |
| Anastrozole | 130 | $1,187 |
| Ondansetron OdtOndansetron | 91 | $1,171 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Odessa
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
- Sue EckhardtAustin$1.5M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Maen AbdelrahimHouston$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.